Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    "methodist hospital" | Open Studies | "Lymphoma, T-Cell" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Alisertib (MLN8237) or Investigator&Apos;s Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib;   Drug: Pralatrexate;   Drug: Gemcitabine;   Drug: Romidepsin

Indicates status has not been verified in more than two years